Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions

View original at finance.yahoo.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake's DCF model fair value is $236.22 per share, implying the stock is trading at a 28.9% discount

    60% confidence

  • Snowflake is 113.1% overvalued based on most popular narrative

    60% confidence

  • The valuation narrative could crack if competitive pressure from Databricks intensifies or if Snowflake's losses and stock based compensation continue to weigh on sentiment

    60% confidence

  • Snowflake is a company that is growing fast and holding a lot of cash, while spending remains high and seeing significant increase in customer revenue

    60% confidence

  • Snowflake's fair value is $78.83 per share based on the most followed valuation narrative

    60% confidence

Data points we hold from this source

Snowflake Inc. · fair value dcf236.22 USD
Snowflake Inc. · fair value narrative78.83 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions — Source | Via News | Via News